Zepbound approved for treating moderate to severe obstructive sleep apnea in adults with obesity, showing improvement in ...

A trial of Eli Lilly’s diabetes drug Mounjaro did not meet expectations for outperforming Trulicity in preventing heart ...

Mustafa Suleyman, who founded DeepMind and sold it to Google, has been telling recruits that Microsoft is now the more startup-like workplace.

It's the miracle drug known to curb appetite, stimulate weight loss and even help kick unhealthy addictions like smoking. But a new side effect has stumped doctors.

Novo Nordisk ( NVO -4.02%) stock imitated the company's leading product on Wednesday by slimming down in price. The Danish pharmaceutical's shares lost nearly 4% of their value following its latest ...

A new study in mice has found that muscle loss associated with weight loss from GLP-1 medications like Ozempic may not be as ...

As announced July 29, Novo Nordisk NVO saw 18% sales growth and 40% operating profit growth at constant currencies in the ...

This podcast was recorded on July 21, 2025. Tim Beyers: Is it time to buy biotech? You're listening to Motley Fool Money.

When Eli Lilly reports its financial results early Thursday, investors will be looking for the company to press its advantage ...

Novo Nordisk stock wavered after its second-quarter earnings report early Wednesday as it vowed to cut costs amid ...

A wave of public alarm over counterfeit and dangerous foreign-made prescription drugs, particularly from China, has reached new heights, according to a recent ...

The Microdose GLP-1Rx Program will offer low-dose GLP-1 prescriptions combined with behavioral coaching, clinical monitoring and medication management.